Cumulative incidence of MACEs, stratified by HTN status during ibrutinib use. Shown is overall incidence of grade 3 or more HTN occurrence at baseline, 3, 6, 9, and 12 months after ibrutinib initiation. Data reflect the JNC-8 HTN cutoff of 140/90 mm Hg for comparison with established HTN prediction models (includes only subjects aged 20-69 years without diabetes). Subjects without known discussion of parenteral history of HTN, were assigned a value of 1 (ie, 1 of 2 parents with HTN) in the Framingham model.¹⁸  JNC-8, Joint National Committee-8.